5 results on '"Karalı Y"'
Search Results
2. Exploring gastrointestinal manifestations in childhood onset systemic lupus erythematosus - Insights from a multicenter study.
- Author
-
Sönmez HE, Batu ED, İşgüder R, Şahin N, Aliyev E, Aslan E, Çoban S, Güngörer V, Karadağ ŞG, Karaçayır N, Kısaoğlu H, Yekedüz Bülbül A, Garip S, Karalı Y, Ayduran S, Demir S, Kaya Akça Ü, Başaran Ö, Şahin S, Kasap B, Kilic SS, Kışla Ekinci RM, Kısaarslan AP, Kalyoncu M, Bakkaloğlu S, Yüksel S, Aktay Ayaz N, Çelikel Acar B, Sözeri B, Kasapçopur Ö, Ünsal E, and Özen S
- Subjects
- Humans, Female, Child, Male, Adolescent, Age of Onset, Abdominal Pain etiology, Child, Preschool, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic diagnosis, Gastrointestinal Diseases etiology, Gastrointestinal Diseases epidemiology
- Abstract
Objective: Systemic lupus erythematosus (SLE) constitutes an autoimmune disorder with potential involvement of the gastrointestinal system (GIS). Our objective was to assess the gastrointestinal (GI) manifestations in patients diagnosed with childhood onset SLE., Methods: The study cohort consisted of 123 patients with childhood onset-SLE and GIS involvement from 16 referral departments of pediatric rheumatology. All participants met the Systemic Lupus International Collaborating Clinics criteria., Results: Out of 123 patients, 78 (63.4%) exhibited GIS involvement at the initial SLE diagnosis, whereas the remaining 45 (36.6%) developed GI symptoms after a median duration of 12 (3-140) months. Eighty-two (66.7%) individuals experienced symptoms related to the GI tract, whereas the remaining patients received a diagnosis of GI involvement through laboratory assessments. The predominant initial GIS involvement symptom was abdominal pain, observed in 77 (62.6%) patients, followed by elevated hepatic transaminases in 70 (56.9%), hepatomegaly in 40 (32.5%), diarrhea in 26 (21.1%), and jaundice in 11 (8.9%) patients. The GIS involvement was associated with SLE in 82 (78.6%), while it resulted from drug-related adverse events in 35 (28.5%) patients or comorbidities in 6 (0.5%) patients., Conclusion: GIS involvement should be considered in all childhood onset-SLE patients, especially in the presence of suggestive symptoms or elevated hepatic transaminases. It is also crucial to consider SLE in the differential diagnosis of GIS manifestations in children. Apart from GIS involvement directly associated with SLE, adverse events of drugs should be kept in mind., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
3. Evaluation of pulmonary findings in patients with humoral immunodeficiency.
- Author
-
Karalı Z, Karalı Y, Çekiç Ş, Yazıcı Z, Canıtez Y, Sapan N, and Gültekin SŞK
- Abstract
Aim: To determine the frequency of sinopulmonary infections, detect changes in the respiratory system, and measure functional capacity of the lungs in our patients with humoral immunodeficiency., Material and Methods: Fifty-six patients with humoral immunodeficiency were enrolled in this study. The clinical, laboratory, and radiologic data, and pulmonary function tests of the subjects were evaluated from their file records, retrospectively., Results: The distribution of our patients was as follows: 25 patients had common variable immune deficiency, three patients had X-linked agammaglobulinemia, five patients had hyper immunoglobulin M syndrome, 19 patients had deficiency of immunoglobulin G subset, and four patients had selective immunoglobulin A deficiency. The most common symptom of the patients was chronic cough (n=47, 83.9%). The most common pathologies on high-resolution computed tomography of the chest were atelectasis and bronchiectasis (27.7%). The most common pathology in pulmonary function tests was the presence of moderate obstructive patterns along with restrictive patterns (n=6,12.5%). The FEV 1, FVC, and FEF 25-75 values were significantly lower in patients with common variable immunodeficiency compared with the patients who had IgG subset deficiencies (p=0.001, p=0.01, p=0.01). Among the patients who were treated with intravenous immunoglobulin, the age at the diagnosis of immunodeficiency was higher in patients with bronchiectasis (14.2±8.4 years) compared with those without bronchiectasis (10.1±11.4 years) (p=0.04)., Conclusion: Clinical findings are not sufficient to monitor the structural and functional changes in the respiratory system, and patients should be evaluated using high-resolution computed tomography of the chest and pulmonary function tests., Competing Interests: Conflict of Interest: The authors have no conflicts of interest to declare., (Copyright: © 2020 Turkish Archives of Pediatrics.)
- Published
- 2020
- Full Text
- View/download PDF
4. Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?
- Author
-
Çekiç Ş, Özgür T, Karalı Y, Özkan T, and Kılıç SŞ
- Subjects
- Agammaglobulinaemia Tyrosine Kinase genetics, Agammaglobulinaemia Tyrosine Kinase metabolism, Agammaglobulinemia diagnosis, Agammaglobulinemia genetics, Child, Preschool, DNA genetics, DNA Mutational Analysis, Gastrointestinal Agents therapeutic use, Genetic Diseases, X-Linked diagnosis, Genetic Diseases, X-Linked genetics, Humans, Magnetic Resonance Imaging, Male, Mutation, Agammaglobulinemia drug therapy, Antibodies, Monoclonal, Humanized therapeutic use, Genetic Diseases, X-Linked drug therapy
- Abstract
Çekiç Ş, Özgür T, Karalı Y, Özkan T, Kılıç SŞ. Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient? Turk J Pediatr 2019; 61: 937-940. The loss of inflammatory regulation resulting from the absence of B-lymphocytes leads to a risk for autoimmune and autoinflammatory complications. There is no data on the use of Vedolizumab in patients with X-linked agammaglobulinemia (XLA) as well as children with another primary immunodeficiency (PID) diseases. A 4-year-old boy was admitted to our clinic with a history of recurrent respiratory tract infections. He was diagnosed with XLA based on extremely low immunoglobulins, very low level of B cells, genetic mutation of BTK gene, and family history. At the age of 8, he suffered from intermittent fever attacks, abdominal pain, weakness, oral aft, and weight loss. His clinical and laboratory features were consistent with inflammatory bowel disease. Histopathological examination of the biopsy material obtained from terminal ileum, colon and cecum showed Crohn`s disease. Initially, he was treated with prednisolone and infliximab. Because of the lack of response, infliximab treatment was switched to adalimumab. Terminal ileum was resected to relieve obstruction complication. Although he had been treated with adalimumab, a significant improvement was not observed. Vedolizumab (Entyvio™), a humanized monoclonal antibody α4β7 integrin-receptor antagonist, was commenced. After treatment with vedolizumab, his fever and abdominal pain attacks reduced, his total daily calorie intake increased and weight gain improved. He began to walk again and continued his school education properly. No side effects were observed in 18 months. This is the first immunocompromised child treated with vedolizumab. The symptoms of the patient receded and no side effect were seen during the treatment.
- Published
- 2019
- Full Text
- View/download PDF
5. Use of complementary and alternative medicine in children with cancer: effect on survival.
- Author
-
Karalı Y, Demirkaya M, and Sevinir B
- Subjects
- Adolescent, Child, Child, Preschool, Disease-Free Survival, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Survival Rate, Complementary Therapies methods, Dietary Supplements, Honey, Neoplasms mortality, Neoplasms therapy, Plants, Medicinal, Urtica dioica
- Abstract
The objective of the present study was to determine the type, frequency, the reason why complementary and alternative medicine (CAM) treatments are used, the factors related with their use, and the effects of CAM usage on long-term survival. Families of a total of 120 children with cancer between 0-18 years of age, including 50 (41.7%) girls and 70 (58.3%) boys, participated in our study. The authors found that 88 patients (73.3%) used at least one CAM method, the most common (95.5%) of which was biologically based therapies. Most frequently used biologically based therapies were dietary supplements and herbal products. The most commonly used dietary supplement or herbal product was honey (43.2%) or stinging nettle (43.2%), respectively. We found that patients used such CAM methods as complementary to, but not instead of, conventional therapy. Sixty-nine out of 88 patient families (78.4%) shared the CAM method they used with their physicians. No statistically significant relation was found between socioeconomic, sociodemographic, or other factors or items and CAM use. The mean follow-up period of the CAM users and nonusers groups was 79.4 ± 36.7 (21.3-217.9) and 90.9 ± 50.3 (27.4-193.7) months, respectively. Five-year survival rates for CAM users and nonusers were found as 81.5% and 86.5%, respectively (P > .05). In conclusion, families of children with cancer use complementary and alternative treatment frequently. They do not attempt to replace conventional treatment with CAM. Higher rates of CAM use was found in families with higher educational level. CAM usage did not affect the long-term survival.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.